We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.6%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$72.7B
AUM Growth
+$7.54B
(+12%)
Cap. Flow
-$3.34B
Cap. Flow
% of AUM
-4.6%
Top 10 Holdings %
Top 10 Hldgs %
23.55%
Holding
2,585
New
253
Increased
940
Reduced
728
Closed
298
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crown Castle
CCI
|
+$536M |
| 2 |
Procter & Gamble
PG
|
+$358M |
| 3 |
CSX Corp
CSX
|
+$303M |
| 4 |
NVIDIA
NVDA
|
+$186M |
| 5 |
Eli Lilly
LLY
|
+$185M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$370M |
| 2 |
American Electric Power
AEP
|
+$338M |
| 3 |
Alibaba
BABA
|
+$322M |
| 4 |
Prologis
PLD
|
+$307M |
| 5 |
HEICO Corp
HEI
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.03% |
| 2 | Financials | 13.75% |
| 3 | Industrials | 12.1% |
| 4 | Healthcare | 10.45% |
| 5 | Consumer Discretionary | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Harmony Biosciences
HRMY
$2.26B
| $2.49M | ﹤0.01% |
78,743
-36,110
| -31% | -$1.16M |
|
|
UNIT
752
Uniti Group
UNIT
$2.33B
| $2.48M | ﹤0.01% |
573,663
-388,543
| -40% | -$1.74M |
|
753
Federated Hermes
FHI
$4.72B
| $2.47M | ﹤0.01% |
55,687
+53,691
| +2,690% | +$2.21M |
|
754
Progress Software
PRGS
$1.71B
| $2.46M | ﹤0.01% |
38,624
-5,468
| -12% | -$333K |
|
755
iRadimed
IRMD
$1.17B
| $2.46M | ﹤0.01% |
41,110
+2,036
| +5% | +$112K |
|
756
Medpace
MEDP
$16.3B
| $2.46M | ﹤0.01% |
7,831
-19,981
| -72% | -$6M |
|
757
Resideo Technologies
REZI
$3.95B
| $2.46M | ﹤0.01% |
111,327
+5,373
| +5% | +$103K |
|
758
Edwards Lifesciences
EW
$51.5B
| $2.45M | ﹤0.01% |
31,372
+23,496
| +298% | +$1.75M |
|
759
PROG Holdings
PRG
$1.73B
| $2.45M | ﹤0.01% |
+83,444
| New | +$2.32M |
|
760
Iris Energy
IREN
$13.6B
| $2.44M | ﹤0.01% |
167,518
+167,303
| +77,815% | +$1.36M |
|
761
KKR & Co
KKR
$92.8B
| $2.44M | ﹤0.01% |
18,327
-5,416
| -23% | -$634K |
|
762
Virtu Financial
VIRT
$4.91B
| $2.43M | ﹤0.01% |
54,209
+37,860
| +232% | +$1.53M |
|
763
SentinelOne
S
$7.12B
| $2.42M | ﹤0.01% |
132,319
+55,816
| +73% | +$1.02M |
|
|
VRNA
764
DELISTED
Verona Pharma
VRNA
| $2.4M | ﹤0.01% |
25,436
+1,309
| +5% | +$96.9K |
|
765
Ionis Pharmaceuticals
IONS
$9.06B
| $2.4M | ﹤0.01% |
60,749
-9
| -0% | -$295 |
|
|
AGS
766
DELISTED
PlayAGS
AGS
| $2.38M | ﹤0.01% |
+190,885
| New | +$2.33M |
|
767
Belden
BDC
$5.05B
| $2.38M | ﹤0.01% |
20,595
+11,558
| +128% | +$1.22M |
|
768
Sprout Social
SPT
$492M
| $2.38M | ﹤0.01% |
114,060
+26,907
| +31% | +$570K |
|
769
NNN REIT
NNN
$9.02B
| $2.38M | ﹤0.01% |
55,040
+33,552
| +156% | +$1.39M |
|
770
Yelp
YELP
$1.38B
| $2.37M | ﹤0.01% |
69,245
+5,354
| +8% | +$193K |
|
771
Chipotle Mexican Grill
CMG
$42.7B
| $2.37M | ﹤0.01% |
42,135
-14,234
| -25% | -$724K |
|
|
NUTX
772
Nutex Health
NUTX
$1.05B
| $2.36M | ﹤0.01% |
18,989
+18,676
| +5,967% | +$2.41M |
|
773
Phibro Animal Health
PAHC
$1.44B
| $2.36M | ﹤0.01% |
92,441
+89,794
| +3,392% | +$1.96M |
|
774
Rivian
RIVN
$22.3B
| $2.36M | ﹤0.01% |
+171,800
| New | +$2.33M |
|
775
FTI Consulting
FCN
$4.17B
| $2.35M | ﹤0.01% |
14,555
+653
| +5% | +$107K |
|
Similar funds
QCM
Lazard Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Lazard Asset Management held 2,585 positions worth $72.7B, up 12% from $65.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $3.34B in Q2 2025, closing 298 positions and reducing 728 holdings. Its most notable exit was Eastman Chemical, an estimated $13.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Industrials.
Against the trend, Lazard Asset Management opened a new position in Arcos Dorados Holdings worth $117M.
- Lazard Asset Management's largest Q2 2025 buy was Arcos Dorados Holdings: 14,873,278 shares worth $117M.
- Lazard Asset Management added most to Crown Castle in Q2 2025, an estimated $536M increase.
- Lazard Asset Management's biggest Q2 2025 reduction was NetEase, cutting an estimated $370M.
- Lazard Asset Management fully exited Eastman Chemical in Q2 2025, selling an estimated $13.1M.
- Lazard Asset Management's ten largest holdings make up 24% of its $72.7B portfolio in Q2 2025.
- Lazard Asset Management opened 253 new positions and closed 298 in Q2 2025.
- Lazard Asset Management's portfolio value rose 12% quarter-over-quarter to $72.7B.
Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.